2876-LB: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2876-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von HUSAM A. GHANIM und 8 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: Adjunct therapy with non-insulin glucose-lowering agents is an attractive therapeutic strategy in type 1 diabetes (T1D) but carries risks of hypoglycemia and ketosis. We assessed the efficacy and safety of adding semaglutide weekly injection and oral dapagliflozin in with insulin therapy in overweight (BMI > 25 kg/m2) adults with T1D and HbA1c 7.5 - 11.0 % inclusive.
Methods
In Period 1 (weeks 1 to 26) participants were randomized 2:1 (open label) to standard of care (SOC) insulin treatment with or without semaglutide (uptitrated to 1.0 mg weekly); in Period 2 (weeks 26 to 52), those randomized to semaglutide were further randomized (double-blind) to dapagliflozin (10 mg daily) or placebo. The primary outcome was change in HbA1c in Period 2. Hypoglycaemia and ketoacidosis were key safety outcomes. Analysis was by intention-to-treat.
Results
78 adults with T1D (aged 45±13.7 years, 51% female, HbA1c 8.3±0.7%, BMI 33±6.1 kg/m2) were randomized in Period 1 and 36 in Period 2. In Period 1, HbA1c was reduced by 0.45% (95% CI -0.78, -0.127; p=0.0072) and body weight was reduced by 10.2 kg (95% CI -12.8, - 7.7; p<0.0001) by semaglutide vs SOC. In Period 2, HbA1c was further reduced by 0.46% (95% CI -0.78, -0.14; p=0.003) by dapagliflozin vs placebo (primary outcome) but body weight was not further reduced (-1.0 kg; 95% CI -2.72, 0.66; p=0.2219). Over Periods 1&2 (52 weeks), HbA1c was reduced by 0.36% (95% CI -0.67, -0.05; p=0.0235) in those randomized to semaglutide and dapagliflozin vs SOC. Time below Range was not affected by either treatment but more Level 2 hypoglycemia events occurred on semaglutide than on SOC in Period 1 [17 vs 9 events per patient year, incidence rate ratio 2.6, 95% CI 1.4, 5.0, p=0.0047). One episode of ketoacidosis occurred in a participant randomized to placebo in Period 2.
Conclusion
Semaglutide adjunct therapy reduced HbA1c and body weight in overweight adults with T1D; HbA1c was further reduced by addition of dapagliflozin. Semaglutide was associated with an initial excess of Level 2 hypoglycemia. Disclosure H.A. Ghanim: None. J.G. Timmons: None. N. Greenlaw: Other - Grant to my institution for the TTT1 study; Current; JDRF. A. McConnachie: None. A. Chaudhuri: Consultant; Current; Lilly. Research Support; Current; Lilly. Consultant; Current; Novo Nordisk. Research Support; Current; Novo Nordisk, AbbVie Inc., Inventiva Pharma, Akero Therapeutics, Inc. M.A. Batra: None. J.G. Boyle: None. P.A. Dandona: None. J.R. Petrie: Other - Endpoint Committee Member; Current; Boehringer Ingelheim International GmbH, IQVIA Inc. Research Support; Ended; Merck KGaA, Novo Nordisk A/S. Other - Travel support; Ended; Sanofi. Advisory Panel; Ended; Sanofi. Other - Donation and discounting of sensors for use in clinical trial; Ended; Dexcom, Inc. Funding Breakthrough-T1D (3-SRA-2019-669-M-B)
Zitieren
APA
GHANIM, H. A., TIMMONS, J. G., GREENLAW, N., MCCONNACHIE, A., CHAUDHURI, A., BATRA, M. A., BOYLE, J. G., DANDONA, P. A., & PETRIE, J. R. (2026). 2876-LB: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2876-lb
Vancouver
GHANIM HA, TIMMONS JG, GREENLAW N, MCCONNACHIE A, CHAUDHURI A, BATRA MA, et al. 2876-LB: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2876-lb
BibTeX
@article{GHANIM2026,
author = {GHANIM, HUSAM A. and TIMMONS, JOSEPH G. and GREENLAW, NICOLA and MCCONNACHIE, ALEX and CHAUDHURI, AJAY and BATRA, MANAV A. and BOYLE, JAMES G. and DANDONA, PARESH A. and PETRIE, JOHN R.},
title = {2876-LB: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2876-lb}
}
EUVIMED